Compare CIVB & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIVB | PRME |
|---|---|---|
| Founded | 1884 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.3M | 536.4M |
| IPO Year | 2012 | 2022 |
| Metric | CIVB | PRME |
|---|---|---|
| Price | $25.56 | $3.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $26.60 | $7.56 |
| AVG Volume (30 Days) | 51.4K | ★ 2.6M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 31.34 | 18.18 |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $19,023,000.00 | $4,632,000.00 |
| Revenue This Year | $14.88 | $7.06 |
| Revenue Next Year | $5.99 | $47.01 |
| P/E Ratio | $35.50 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $18.95 | $1.29 |
| 52 Week High | $26.15 | $6.94 |
| Indicator | CIVB | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 58.66 | 54.33 |
| Support Level | $21.39 | $3.15 |
| Resistance Level | $25.99 | $3.97 |
| Average True Range (ATR) | 0.68 | 0.22 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 70.21 | 84.30 |
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.